Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Oct;187(1):11-12.
doi: 10.1111/bjh.16012. Epub 2019 Jun 6.

Less iron improves MDS haematopoiesis

Emmanuel Gyan  1   2 , Antonio M Almeida  3
Affiliations
Editorial

Less iron improves MDS haematopoiesis

Emmanuel Gyan et al. Br J Haematol. 2019 Oct.
No abstract available

Keywords: iron overload; lower-risk myelodysplastic syndromes; transfusion-related iron overload.

PubMed Disclaimer

Comment on

References

    1. Angelucci, E., Santini, V., Di Tucci, A.A., Quaresmini, G., Finelli, C., Volpe, A., Quarta, G., Rivellini, F., Sanpaolo, G., Cilloni, D., Salvi, F., Caocci, G., Molteni, A., Vallisa, D., Voso, M.T., Fenu, S., Borin, L., Latte, G., Alimena, G., Storti, S., Piciocchi, A., Fazi, P., Vignetti, M. & Tura, S. (2014) Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). European Journal of Haematology, 92, 527-536.
    1. Angelucci, E., Li, J., Greenberg, P.L., Depei, W., Hou, M., Montaño Figueroa, E., Rodriguez, G., Dong, X., Ghosh, J., Bornstein, O. & Garcia-Manero, G. (2018) Safety and efficacy, including event-free survival, of deferasirox versus placebo in iron-overloaded patients with low- and int-1-risk myelodysplastic syndromes (MDS): outcomes from the randomized, double-blind telesto study. Blood, 132, 234-234.
    1. Fabiani, E., Calabrese, C., Niscola, P., Balleari, E., Molteni, A., Finelli, C., Falconi, G., Fenu, S., Fianchi, L., Criscuolo, M., Salvi, F., Lavorgna, S., Buccisano, F., Maurillo, L., Lo Coco, F., Cilloni, D. & Voso, M.T. (2019) Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (MDS). British Journal of Haematology, 185, 954-957. https://doi.org/10.1111/bjh.15655.
    1. Gattermann, N. (2008) Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. International journal of hematology, 88, 24-29.
    1. Gattermann, N., Finelli, C., Della Porta, M., Fenaux, P., Stadler, M., Guerci-Bresler, A., Schmid, M., Taylor, K., Vassilieff, D., Habr, D., Marcellari, A., Roubert, B. & Rose, C. (2012) Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica, 97, 1364-1371.

LinkOut - more resources